---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-080765"
form_type: "8-K"
ticker: null
cik: "0001971543"
company_name: "Mural Oncology plc"
filed_at: "2025-04-15T23:59:59+00:00"
generated_at: "2026-05-23T15:04:58.028862+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Mural Oncology ends nemvaleukin alfa development, cuts 90% of staff

## Summary
- Discontinues all clinical development of nemvaleukin alfa after phase 2 ARTISTRY-6 and phase 3 ARTISTRY-7 trial data.
- Workforce reduction of approximately 104 positions, or about 90%, expected to complete by end of Q2 2025.
- Estimated costs of $9.0-$10.0 million in severance and benefits, plus $2.0-$4.0 million in non-cash impairment charges.
- Engages Lucid Capital Markets to explore strategic alternatives focused on maximizing shareholder value.

## SEC filing metadata
- accession: 0001193125-25-080765
- form_type: 8-K
- cik: 0001971543
- company_name: Mural Oncology plc
- filed_at: 2025-04-15T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.05, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971543/000119312525080765/0001193125-25-080765-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971543/000119312525080765/d940480d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-080765
- JSON: https://secwatch.observer/filing/0001193125-25-080765.json
- Plain text: https://secwatch.observer/filing/0001193125-25-080765.txt

## Key facts
- Restructurings & Charges
  Mural Oncology plc announced a restructuring with charges of approximately $9.0 million to $10.0 million (approximately 104 positions, or approximately 90%).
  - Type: restructuring
  - Charge: approximately $9.0 million to $10.0 million
  - Headcount: approximately 104 positions, or approximately 90%
  source text: 90% (the “Reduction”). The Company expects to substantially complete the Reduction by the end of the second quarter of 2025. The Company expects to incur costs of approximately $9.0 million to $10.0 million related to the Reduction, primarily consisting of severance payments and employee benefit costs. Additionally, the Company expects to incur $2.0 million to $4.0
  evidence_url: https://www.sec.gov/Archives/edgar/data/1971543/000119312525080765/0001193125-25-080765-index.htm
- Restructurings & Charges
  Mural Oncology plc announced a impairment with charges of $2.0 million to $4.0 million affecting property and equipment.
  - Type: impairment
  - Charge: $2.0 million to $4.0 million
  - Affected area: property and equipment
  source text: Additionally, the Company expects to incur $2.0 million to $4.0 million in non-cash impairment charges associated with property and equipment expected to be sold or otherwise disposed of.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1971543/000119312525080765/0001193125-25-080765-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.